| Name | Title | Contact Details |
|---|
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
NeuroVista Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.